Westerbacka相关文献与解析，生知库 | 链接生命科学的每一步

Continuous glucose monitoring-based time-in-range using insulin glargine 300 units/ml versus insulin degludec 100 units/ml in type 1 diabetes: The head-to-head randomized controlled InRange trial

在1型糖尿病患者中，使用甘精胰岛素300单位/毫升与德谷胰岛素100单位/毫升进行基于持续血糖监测的目标范围内时间评估：InRange头对头随机对照试验

Battelino, Tadej; Danne, Thomas; Edelman, Steve V; Choudhary, Pratik; Renard, Eric; Westerbacka, Jukka; Mukherjee, Bhaswati; Pilorget, Valerie; Coudert, Mathieu; Bergenstal, Richard M

代谢

Real-world outcomes of addition of insulin glargine 300 U/mL (Gla-300) to glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy in people with type 2 diabetes: The DELIVER-G study

在 2 型糖尿病患者中，将甘精胰岛素 300 U/mL (Gla-300) 添加到胰高血糖素样肽-1 受体激动剂 (GLP-1 RA) 治疗方案中的真实世界结果：DELIVER-G 研究

期刊:Diabetes Obesity & Metabolism

影响因子:5.7

doi:10.1111/dom.14739

Bailey, Timothy S; Gill, Jasvinder; Jones S, Merwyn; Shenoy, Laxmi; Nicholls, Charlie; Westerbacka, Jukka

Clinical outcomes in high-hypoglycaemia-risk patients with type 2 diabetes switching to insulin glargine 300 U/mL versus a first-generation basal insulin analogue in the United States : Results from the DELIVER High Risk real-world study

美国高低血糖风险2型糖尿病患者改用甘精胰岛素300 U/mL与第一代基础胰岛素类似物治疗的临床结局：来自DELIVER高风险真实世界研究的结果

期刊:Endocrinology, Diabetes and Metabolism

影响因子:2.6

doi:10.1002/edm2.306

Sullivan, Sean D; Freemantle, Nick; Gupta, Rishab A; Wu, Jasmanda; Nicholls, Charlie J; Westerbacka, Jukka; Bailey, Timothy S

How many people with type 2 diabetes fulfil the eligibility criteria for randomized, controlled trials of insulin glargine 300 U/mL in a real-world setting?

在真实世界中，有多少 2 型糖尿病患者符合随机对照试验（胰岛素甘精 300 U/mL）的入选标准？

期刊:Diabetes Obesity & Metabolism

影响因子:5.7

doi:10.1111/dom.14264

Mauricio, Dídac; Westerbacka, Jukka; Nicholls, Charlie; Wu, Jasmanda; Gupta, Rishab; Eliasson, Björn

Glycaemic control and hypoglycaemia risk with insulin glargine 300 U/mL and insulin degludec 100 U/mL in older participants in the BRIGHT trial

BRIGHT试验中老年受试者使用甘精胰岛素300 U/mL和德谷胰岛素100 U/mL时的血糖控制和低血糖风险

期刊:Diabetes Obesity & Metabolism

影响因子:5.7

doi:10.1111/dom.14372

Bolli, Geremia B; Cheng, Alice; Charbonnel, Bernard; Aroda, Vanita R; Westerbacka, Jukka; Bosnyak, Zsolt; Boëlle-Le Corfec, Emmanuelle; Rosenstock, Julio

免疫/内分泌

发表日期：2021

文献求助收藏

A review of reusable insulin pens and features of TouStar-a new reusable pen with a dedicated cartridge

本文评测了可重复使用的胰岛素笔，并重点介绍了 TouStar——一款配备专用笔芯的新型可重复使用胰岛素笔。

期刊:Diabetology & Metabolic Syndrome

影响因子:3.9

doi:10.1186/s13098-021-00763-z

Veasey, Robert; Ruf, Carolin A; Bogatirsky, Dmitri; Westerbacka, Jukka; Friedrichs, Arnd; Abdel-Tawab, Mona; Adler, Steffen; Mohanasundaram, Senthilnathan

免疫/内分泌

发表日期：2021

文献求助收藏

Similar glycaemic control and less hypoglycaemia during active titration after insulin initiation with glargine 300 units/mL and degludec 100 units/mL: A subanalysis of the BRIGHT study

在胰岛素起始治疗后，使用甘精胰岛素 300 单位/毫升和德谷胰岛素 100 单位/毫升进行主动滴定期间，血糖控制相似，且低血糖发生率更低：BRIGHT 研究的子分析

期刊:Diabetes Obesity & Metabolism

影响因子:5.7

doi:10.1111/dom.13901

Cheng, Alice; Harris, Stewart; Giorgino, Francesco; Seufert, Jochen; Ritzel, Robert; Khunti, Kamlesh; Lauand, Felipe; Melas-Melt, Lydie; Westerbacka, Jukka; Bosnyak, Zsolt; Rosenstock, Julio

免疫/内分泌

发表日期：2020

文献求助收藏

Differential glycaemic control with basal insulin glargine 300 U/mL versus degludec 100 U/mL according to kidney function in type 2 diabetes: A subanalysis from the BRIGHT trial

根据肾功能评估 2 型糖尿病患者使用基础胰岛素甘精 300 U/mL 与德谷胰岛素 100 U/mL 的血糖控制差异：BRIGHT 试验的亚组分析

期刊:Diabetes Obesity & Metabolism

影响因子:5.7

doi:10.1111/dom.14043

Haluzík, Martin; Cheng, Alice; Müller-Wieland, Dirk; Westerbacka, Jukka; Bosnyak, Zsolt; Lauand, Felipe; Melas-Melt, Lydie; Karalliedde, Janaka; Rosenstock, Julio; Bolli, Geremia B

The Diabetes Unmet Need with Basal Insulin Evaluation (DUNE) study in type 2 diabetes: Achieving HbA1c targets with basal insulin in a real-world setting

糖尿病基础胰岛素治疗未满足需求评估（DUNE）研究：在真实世界环境中使用基础胰岛素达到HbA1c目标

期刊:Diabetes Obesity & Metabolism

影响因子:5.7

doi:10.1111/dom.13673

Meneghini, Luigi F; Mauricio, Didac; Orsi, Emanuela; Lalic, Nebojsa M; Cali, Anna M G; Westerbacka, Jukka; Stella, Peter; Candelas Dea, Christophe; Pilorget, Valerie; Perfetti, Riccardo; Khunti, Kamlesh

Insulin glargine 300 U/mL safety data in pregnancy

妊娠期胰岛素甘精300 U/mL安全性数据

Continuous glucose monitoring-based time-in-range using insulin glargine 300 units/ml versus insulin degludec 100 units/ml in type 1 diabetes: The head-to-head randomized controlled InRange trial

在1型糖尿病患者中，使用甘精胰岛素300单位/毫升与德谷胰岛素100单位/毫升进行基于持续血糖监测的目标范围内时间评估：InRange头对头随机对照试验

Real-world outcomes of addition of insulin glargine 300 U/mL (Gla-300) to glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy in people with type 2 diabetes: The DELIVER-G study

在 2 型糖尿病患者中，将甘精胰岛素 300 U/mL (Gla-300) 添加到胰高血糖素样肽-1 受体激动剂 (GLP-1 RA) 治疗方案中的真实世界结果：DELIVER-G 研究

Clinical outcomes in high-hypoglycaemia-risk patients with type 2 diabetes switching to insulin glargine 300 U/mL versus a first-generation basal insulin analogue in the United States : Results from the DELIVER High Risk real-world study

美国高低血糖风险2型糖尿病患者改用甘精胰岛素300 U/mL与第一代基础胰岛素类似物治疗的临床结局：来自DELIVER高风险真实世界研究的结果

How many people with type 2 diabetes fulfil the eligibility criteria for randomized, controlled trials of insulin glargine 300 U/mL in a real-world setting?

在真实世界中，有多少 2 型糖尿病患者符合随机对照试验（胰岛素甘精 300 U/mL）的入选标准？

Glycaemic control and hypoglycaemia risk with insulin glargine 300 U/mL and insulin degludec 100 U/mL in older participants in the BRIGHT trial

BRIGHT试验中老年受试者使用甘精胰岛素300 U/mL和德谷胰岛素100 U/mL时的血糖控制和低血糖风险

A review of reusable insulin pens and features of TouStar-a new reusable pen with a dedicated cartridge

本文评测了可重复使用的胰岛素笔，并重点介绍了 TouStar——一款配备专用笔芯的新型可重复使用胰岛素笔。

Similar glycaemic control and less hypoglycaemia during active titration after insulin initiation with glargine 300 units/mL and degludec 100 units/mL: A subanalysis of the BRIGHT study

在胰岛素起始治疗后，使用甘精胰岛素 300 单位/毫升和德谷胰岛素 100 单位/毫升进行主动滴定期间，血糖控制相似，且低血糖发生率更低：BRIGHT 研究的子分析

Differential glycaemic control with basal insulin glargine 300 U/mL versus degludec 100 U/mL according to kidney function in type 2 diabetes: A subanalysis from the BRIGHT trial

根据肾功能评估 2 型糖尿病患者使用基础胰岛素甘精 300 U/mL 与德谷胰岛素 100 U/mL 的血糖控制差异：BRIGHT 试验的亚组分析

The Diabetes Unmet Need with Basal Insulin Evaluation (DUNE) study in type 2 diabetes: Achieving HbA1c targets with basal insulin in a real-world setting

糖尿病基础胰岛素治疗未满足需求评估（DUNE）研究：在真实世界环境中使用基础胰岛素达到HbA1c目标